Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
J.P. Morgan Healthcare Conference
Sage Therapeutics: What's Next? (NASDAQ:SAGE) | Seeking Alpha
SAGE achieves 77% response rate in clinical trial of SAGE-547
Sage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus - Tinnitus Treatment Report
Chunky Knitted Sweater | SAGE – Kloop Kids
SEC Filing | Sage Therapeutics, Inc.
SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in
1. PROTOCOL AND AMENDMENTS
Sage and Marinus – Not the typical CNS story | Open Reading Frame
Sage Therapeutics, Competitive Strategy Report
Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus | Sage Therapeutics, Inc.
Oral Allopregnanolone Analogue for Postpartum Depression Treatment - MGH Center for Women's Mental Health
Sage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus - Tinnitus Treatment Report
Sage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus - Tinnitus Treatment Report
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial - The Lancet
sage-10k_20161231.htm
SEC Filing | Sage Therapeutics, Inc.
SEC Filing | Sage Therapeutics, Inc.
SAGE-547: Novel Treatment for Severe Postpartum Depression
Depressione Post Partum: in studio il farmaco Sage-547 - Valerio Rosso
sage-10k_20161231.htm
Form 10-K
dough on Twitter: "@BioStocks BMO $SAGE SAGE-547 PPD Program Accelerated; Raising PPD Estimates and Price Target https://t.co/dOGReYzSyh" / Twitter
